Key points from article :
Calico and AbbVie announced clinical-stage programs in immuno-oncology and neurodegeneration, currently in Phase I studies.
More than 20 active programs in discovery or preclinical development in age-related diseases.
Calico immuno-oncology program is focused on PTPN2 inhibitors.
ABBV-CLS-579 and ABBV-CLS-484 are novel, orally bioavailable PTPN2 inhibitors.
Developed by Calico in collaboration with AbbVie and the Broad Institute of MIT and Harvard.
Lead Calico neurodegeneration molecule (ABBV-CLS-7262) targets stress response pathway.
Therapeutic potential in neurodegenerative diseases, such as ALS, Parkinson’s disease and traumatic brain injury.
Plans to begin a study later this year in patients with ALS.
ABBV-CLS-7262 is licensed from the lab of Peter Walter, Professor of Biochemistry and Biophysics.
"These are early days, but we are looking forward to potential proof-of-concept data from both programs," - Arthur D. Levinson, Founder and CEO of Calico.
